181 related articles for article (PubMed ID: 21330323)
1. Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response.
Colado E; Paíno T; Maiso P; Ocio EM; Chen X; Alvarez-Fernández S; Gutiérrez NC; Martín-Sánchez J; Flores-Montero J; San Segundo L; Garayoa M; Fernández-Lázaro D; Vidriales MB; Galmarini CM; Avilés P; Cuevas C; Pandiella A; San-Miguel JF
Haematologica; 2011 May; 96(5):687-95. PubMed ID: 21330323
[TBL] [Abstract][Full Text] [Related]
2. Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks.
Ocio EM; Maiso P; Chen X; Garayoa M; Alvarez-Fernández S; San-Segundo L; Vilanova D; López-Corral L; Montero JC; Hernández-Iglesias T; de Alava E; Galmarini C; Avilés P; Cuevas C; San-Miguel JF; Pandiella A
Blood; 2009 Apr; 113(16):3781-91. PubMed ID: 19020308
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylases 1 and 2 cooperate in regulating BRCA1, CHK1, and RAD51 expression in acute myeloid leukemia cells.
Zhao J; Xie C; Edwards H; Wang G; Taub JW; Ge Y
Oncotarget; 2017 Jan; 8(4):6319-6329. PubMed ID: 28030834
[TBL] [Abstract][Full Text] [Related]
4. Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells.
Li Y; Wang Y; Zhou Y; Li J; Chen K; Zhang L; Deng M; Deng S; Li P; Xu B
Clin Epigenetics; 2017; 9():83. PubMed ID: 28814980
[TBL] [Abstract][Full Text] [Related]
5. Panobinostat enhances cytarabine and daunorubicin sensitivities in AML cells through suppressing the expression of BRCA1, CHK1, and Rad51.
Xie C; Drenberg C; Edwards H; Caldwell JT; Chen W; Inaba H; Xu X; Buck SA; Taub JW; Baker SD; Ge Y
PLoS One; 2013; 8(11):e79106. PubMed ID: 24244429
[TBL] [Abstract][Full Text] [Related]
6. The pan-Bcl2 Inhibitor AT101 Activates the Intrinsic Apoptotic Pathway and Causes DNA Damage in Acute Myeloid Leukemia Stem-Like Cells.
Zhang L; Zhou Y; Chen K; Shi P; Li Y; Deng M; Jiang Z; Wang X; Li P; Xu B
Target Oncol; 2017 Oct; 12(5):677-687. PubMed ID: 28710745
[TBL] [Abstract][Full Text] [Related]
7. Venetoclax Synergistically Enhances the Anti-leukemic Activity of Vosaroxin Against Acute Myeloid Leukemia Cells Ex Vivo.
Liu F; Knight T; Su Y; Edwards H; Wang G; Wang Y; Taub JW; Lin H; Sun L; Ge Y
Target Oncol; 2019 Jun; 14(3):351-364. PubMed ID: 31115744
[TBL] [Abstract][Full Text] [Related]
8. Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile.
Cramer-Morales K; Nieborowska-Skorska M; Scheibner K; Padget M; Irvine DA; Sliwinski T; Haas K; Lee J; Geng H; Roy D; Slupianek A; Rassool FV; Wasik MA; Childers W; Copland M; Müschen M; Civin CI; Skorski T
Blood; 2013 Aug; 122(7):1293-304. PubMed ID: 23836560
[TBL] [Abstract][Full Text] [Related]
9. Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis® (PM00104).
Romano M; Frapolli R; Zangarini M; Bello E; Porcu L; Galmarini CM; García-Fernández LF; Cuevas C; Allavena P; Erba E; D'Incalci M
Int J Cancer; 2013 Nov; 133(9):2024-33. PubMed ID: 23588839
[TBL] [Abstract][Full Text] [Related]
10. Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia.
Konopleva M; Tsao T; Ruvolo P; Stiouf I; Estrov Z; Leysath CE; Zhao S; Harris D; Chang S; Jackson CE; Munsell M; Suh N; Gribble G; Honda T; May WS; Sporn MB; Andreeff M
Blood; 2002 Jan; 99(1):326-35. PubMed ID: 11756188
[TBL] [Abstract][Full Text] [Related]
11. Retinoic acid induction of CD38 antigen expression on normal and leukemic human myeloid cells: relationship with cell differentiation.
Prus E; Fibach E
Leuk Lymphoma; 2003 Apr; 44(4):691-8. PubMed ID: 12769347
[TBL] [Abstract][Full Text] [Related]
12. The topoisomerase II inhibitor voreloxin causes cell cycle arrest and apoptosis in myeloid leukemia cells and acts in synergy with cytarabine.
Walsby EJ; Coles SJ; Knapper S; Burnett AK
Haematologica; 2011 Mar; 96(3):393-9. PubMed ID: 21134979
[TBL] [Abstract][Full Text] [Related]
13. Early changes in rpS6 phosphorylation and BH3 profiling predict response to chemotherapy in AML cells.
Grundy M; Jones T; Elmi L; Hall M; Graham A; Russell N; Pallis M
PLoS One; 2018; 13(5):e0196805. PubMed ID: 29723246
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of synergistic antileukemic interactions between valproic acid and cytarabine in pediatric acute myeloid leukemia.
Xie C; Edwards H; Xu X; Zhou H; Buck SA; Stout ML; Yu Q; Rubnitz JE; Matherly LH; Taub JW; Ge Y
Clin Cancer Res; 2010 Nov; 16(22):5499-510. PubMed ID: 20889917
[TBL] [Abstract][Full Text] [Related]
15. The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair.
Maiso P; Colado E; Ocio EM; Garayoa M; Martín J; Atadja P; Pandiella A; San-Miguel JF
Leukemia; 2009 Dec; 23(12):2265-74. PubMed ID: 19812608
[TBL] [Abstract][Full Text] [Related]
16. DNA-PK inhibitor peposertib enhances p53-dependent cytotoxicity of DNA double-strand break inducing therapy in acute leukemia.
Haines E; Nishida Y; Carr MI; Montoya RH; Ostermann LB; Zhang W; Zenke FT; Blaukat A; Andreeff M; Vassilev LT
Sci Rep; 2021 Jun; 11(1):12148. PubMed ID: 34108527
[TBL] [Abstract][Full Text] [Related]
17. Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells.
Kim HP; Gerhard B; Harasym TO; Mayer LD; Hogge DE
Exp Hematol; 2011 Jul; 39(7):741-50. PubMed ID: 21530609
[TBL] [Abstract][Full Text] [Related]
18. Dielectrophoretic Microfluidic Chip Enables Single-Cell Measurements for Multidrug Resistance in Heterogeneous Acute Myeloid Leukemia Patient Samples.
Khamenehfar A; Gandhi MK; Chen Y; Hogge DE; Li PC
Anal Chem; 2016 Jun; 88(11):5680-8. PubMed ID: 27149245
[TBL] [Abstract][Full Text] [Related]
19. Glycogen synthase kinase--3β inhibitors suppress leukemia cell growth.
Song EY; Palladinetti P; Klamer G; Ko KH; Lindeman R; O'Brien TA; Dolnikov A
Exp Hematol; 2010 Oct; 38(10):908-921.e1. PubMed ID: 20540984
[TBL] [Abstract][Full Text] [Related]
20. MDR1 and BCRP1 expression in leukemic progenitors correlates with chemotherapy response in acute myeloid leukemia.
Ho MM; Hogge DE; Ling V
Exp Hematol; 2008 Apr; 36(4):433-42. PubMed ID: 18249061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
